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ABSTRACT
Purpose: To evaluate whether the extent of enteric
diffusion-weighted imaging (DWI) signal abnormality
reflects inflammatory burden inCrohn’s disease (CD), and
to compare qualitative and quantitative grading.
Methods: 69 CD patients (35 male, age 16–78) undergoing
MR enterography with DWI (MRE-D) and the same-day
faecal calprotectin (cohort 1) were supplemented by 29
patients (19 male, age 16–70) undergoing MRE-D and
terminal ileal biopsy (cohort 2). Global (cohort 1) and
terminal ileal (cohort 2) DWI signal was graded (0 to 3) by
2 radiologists and segmental apparent diffusion coefficient
(ADC) calculated. Data were compared to calprotectin
and a validated MRI activity score [MEGS] (cohort 1),
and a histopathological activity score (eAIS) (cohort 2)
using nonparametric testing and rank correlation.
Results: Patients with normal (grades 0 and 1) DWI signal
had lower calprotectin and MEGS than those with
abnormal signal (grades 2 and 3) (160 vs. 492 lg/l,
p = 0.0004, and 3.3 vs. 21, p < 0.0001), respectively.
Calprotectinwas lower if abnormalDWIaffected<10 cm
of small bowel compared to diffuse small and large bowel
abnormality (236 vs. 571 lg, p = 0.009). The sensitivity
and specificity for active disease (calprotectin > 120 lg/l)
were 83% and 52%, respectively. There was a negative
correlation between ileal MEGS and ADC (r = -0.41,
p = 0.017). There was no significant difference in eAIS
between qualitative DWI scores (p = 0.42). Mean ADC
was not different in those with and without histological
inflammation (2077 vs. 1622 9 10-6mm2/s, p = 0.10)
Conclusions:Qualitative grading of DWI signal has utility
in defining the burden of CD activity. Quantitative ADC
measurements have poor discriminatory ability for seg-
mental disease activity.
Key words: Crohns disease—Inﬂammatory bowel
disease (IBD)—Magnetic resonance imaging
(MRI)—Imaging—Diffusion
Magnetic resonance enterography (MRE) is now well
established for the diagnosis and follow-up of Crohn’s
disease [1–7], and there is considerable interest regarding
its potential to quantify inflammation. Knowledge of
inflammatory burden in Crohn’s disease is crucial to
optimize treatment. In general, medication is effective at
reducing inflammation but does not impact the long-s-
tanding fibrotic disease, which often necessitates surgery.
Furthermore, in patients with established inflammation,
monitoring therapeutic efficacy is necessary, so that drugs
can be discontinued and/or replaced if ineffective. Several
MRI activity scoring systems have been proposed and
validated against various reference standards including
histology, calprotectin, and colonoscopy [1, 8–10].
Recent data suggest that diffusion-weighted images
(DWIs) may reﬂect biological activity [11–16]. Diffusion
MRI generates image contrast contingent on the move-
ment of water and other small molecules within tissue.
Cellular infiltration associated with acute inflammation
may alter DWI signal via restriction, so that image
contrast may be related to disease activity.
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Studies of DWI have used a variety of reference
standards for inﬂammatory activity including barium
ﬂuoroscopy, endoscopy, surgical specimens, or even the
MRI itself (raising the possibility of incorporation bias)
[5, 9, 10, 13].
Furthermore, the majority of data supporting DWI
have been obtained at the level of individual bowel seg-
ments (i.e., comparing measurements from a single seg-
ment such as the terminal ileum against a matched
reference standard). In clinical practice, however, patient
management is directed by the overall burden of
inﬂammatory disease in the whole bowel, rather than
from isolated segments. While DWI may be a rapid and
accurate method to stage gastrointestinal inﬂammation
overall, its utility as a global marker of activity has not
been validated. It is also unclear whether simple quali-
tative grading of signal on DWI images is as effective as
more time-consuming quantitative measurements (e.g.,
apparent diffusion coefﬁcient [ADC] calculation).
The primary purpose of this study was to investigate
whether qualitative evaluation of enteric DWI signal
reﬂects overall inﬂammatory disease burden using two
alternate standards of reference for global activity: faecal
calprotectin and a validated MRI activity score. The
beneﬁt, if any, of adding DWI grading to the conven-
tional MRI activity score to predict activity based on
faecal calprotectin levels was also tested. The secondary
purpose was to compare the sensitivity for segmental
disease activity of qualitatively graded DWI images with
calculated ADC measurements, when referenced against
both histopathological and conventional MRI segmental
activity scores.
Methods
Regulatory and ethical approvals were obtained, and all
prospectively recruited patients gave informed written
consent.
Study Population
A retrospective study of two separate patient cohorts was
conducted (Table 1).
Cohort 1
Consecutive adult patients with a histologically proven
diagnosis of small-bowel or colonic Crohn’s disease were
prospectively recruited from a study comparing inﬂam-
matory burden measured using a MRE activity score
against the same-day faecal calprotectin. Patients were
recruited from a single institution with an established
secondary and tertiary inﬂammatory bowel disease ser-
vice between Feb 2010 and Oct 2011. Part of the patient
cohort and the recruitment protocol has previously been
described [8].
Cohort 2
A review of our institutional endoscopic database (from
Nov 2013 to Nov 2014) was undertaken by the study
coordinator (subspecialty-trained GI radiology Fellow
with > 400 MRE case experience) to identify only pa-
tients fulﬁlling the eligibility criteria of (i) histologically
proven diagnosis of Crohn’s disease, (ii) assessment with
MRE including DWI, and (iii) endoscopic terminal ileal
biopsy within 40 days (before or after) of MRI.
MRI protocol
Magnetic resonance enterography (MRE) was per-
formed using standard T2- and T1-weighted images
(Table 2: MRI protocol). A 1.5T (Avanto; Siemens) and
a 3.0T (Achieva; Philips) systems were used as per usual
clinical practice at the recruiting institution. Patients
were fasted for 4 h prior to drinking 1 to 1.5 l of 0.2%
locust bean gum/2.5% mannitol solution at 45 minutes
immediately prior to imaging [17]. Twenty milligrams of
intravenous hyoscine butylbromide (Buscopan; Boeh-
ringer Ingelheim, Ingelheim, Germany) was administered
together with 0.1 mmol/kg gadolinium (3 ml/s injection
using a power injector).
Prior to contrast-enhanced imaging, DWI sequences
were also acquired. Speciﬁcally, free-breathing axial dif-
fusion MRI was performed using an echo-planar imag-
ing (EPI) sequence, and spectrally adiabatic inversion
recovery (SPAIR) was applied for fat-suppression. Six
b-values were obtained (0, 50, 100, 300, 600, 800 mm2/s)
at 3.0T and 5 (0, 50, 100, 300, 600 mm2/s) at 1.5T. 4
signal averages were taken for each b-value.
Table 1. Patient characteristics for Cohorts 1 and 2
Patient details Cohort 1 Cohort 2
Total number 69 29
Male/female, n (%) 34/35 (49/51) 19/9 (66/34)
Median age at inclusion (years) 33 23
Previous intestinal resection, n (%) 30 (43) 2 (7)
Crohn’s disease phenotype
(Montreal classification), n (%)
A1 18 (26) 9 (31)
A2 43 (62) 16 (55)
A3 8 (12) 4 (14)
L1 14 (20) 5 (17)
L2 21 (30) 6 (21)
L3 43 (62) 18 (62)
L4 9 (13) 1 (3)
B1 31 (45) 24 (83)
B2 20 (29) 3 (10)
B3 20 (29) 2 (7)
p 19 (28) 1 (3)
Medication, n (%)
No medication 6 (8) 19 (66)
Aminosalicylates/immunomodulators/
steroids
44 (63) 7 (24)
Biological therapy 19 (28) 3 (10)
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Analysis
Qualitative grading of enteric DWI for evaluating global
disease inﬂammatory activity
Qualitative global DWI grading. Visual assessment of
DWI data from all patients in cohort 1 was performed in
consensus by 2 study readers, sub-specialist GI radiolo-
gists (with 3 and 5 years of experience).
DWI images and ADC maps alone (with no
anatomical images) were uploaded on Osirix, [an open-
source DICOM viewer www.osirix-viewer.com] worksta-
tion for analysis. Readers were blinded to the standard
MR enterography images and to all clinical data but
were aware of the purpose of the study.
Using all available B values, readers in consensus
graded the mural signal intensity of the small bowel as a
whole, and the colon on a 4-point scale (Grade
0—Normal, 1—Probably Normal, 2—Probably Abnor-
mal, 3—Abnormal) with reference to normal bowel,
using the method described by Oto et al [18]. If there
were differing grades of diffusion abnormality within the
small bowel or colon, the highest grade was recorded. In
addition, using electronic calipers, readers measured the
longitudinal extent of abnormal (grade 2 or 3) small-
bowel signal (<10 or ‡10 cm).
Examples of the grading system are shown in ﬁgure 1.
Reference standards-global disease activity.
(a) Calprotectin All patients in cohort 1 provided a stool
sample on the day of MRI examination, which was
used for the same-day measurement of faecal cal-
protectin (fC) (PhiCal; NovaTec Immunodiagnos-
tica, Dietzenbach, Germany)
(b) Global MRI activity score A previously validated
global MRI activity score, the MRE global score
[MEGS], was applied to all datasets in cohort 1 as
part of a previously published study [8]. This was
performed by the study coordinator in consensus
with an experienced subspecialty-trained gastroen-
terologist (2 years of experience of MR enterogra-
phy). In brief, a score is assigned to each of 9
segments (rectum, sigmoid, descending, transverse,
ascending, caecum, terminal ileum, ileum, and jeju-
num) based on qualitative scoring (0–3) of mural
thickness T2 signal, mural enhancement and pattern,
peri mural T2 signal, and colonic haustral loss.
Segmental scores are then multiplied by 1 if seg-
mental disease length is 1 to 5 cm, 2 if> 5 < 15 cm,
and 3 if>15 cm, and a score of 5 then added for the
presence of abscess, fistula, comb sign or lym-
phadenopathy
Comparison of qualitatively graded DWI signal with cal-
culated ADC measurements for evaluating segmental dis-
ease activity
Qualitative segmental DWI evaluation. Both readers in
consensus qualitatively graded DWI signal in the last
5 cm of the terminal ileum in all patients in cohort 2,
again using the criteria of Oto et al. [18], described above.
Readers were blinded to the standard MR enterography
images and to all clinical data and utilized DWI images
and ADC maps alone, uploaded on Osirix.
Table 2. MR Enterography parameters: 1.5 T and 3.0 T
Coronal/axial HASTE Coronal/axial TrueFISP Baseline VIBE DCE VIBE
MRE parameters: 1.5 T
FOV (mm) Variable Variable Variable Variable
No. slices 20/26 25/34 40 40
Stacks 1/3 1/3 1 1
Repetition time (ms) 1200/800 3.98/4.25 3.07 2.73
Echo time (ms) 86/86 1.72/2.13 1.08 0.9
Image matrix 256/256 256/256 256 256
Slice (mm) 4/4 4/4 3.5 3.5
Averages 1 1 1 1
Flip angle 15 15
MRE Parameters: 3.0T
FOV (mm) Variable Variable Variable Variable
No. slices 34/69 36/37 82 80
Stacks 1/1 1/1 1 1
Repetition time (ms) 1200/1100 2.5/3.3 2.3 2.3
Echo time (ms) 80/80 1.24/1.66 1.13 1.04
Image matrix 528/512 400/240 576 224
Slice (mm) 4/4 5/5 2 2
Averages 1 1 1 1
Flip angle 90/90 45/60 10 10
Dynamic contrast-enhanced VIBE commenced at the start of contrast injection and the final time point was used to assess contrast enhancement
HASTE, Half-fourier acquisition single-shot turbo spin echo; TrueFISP, True fast imaging with steady state precision; VIBE, volumetric interpo-
lated breath hold examination
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Quantitative segmental DWI evaluation. The study
coordinator reviewed the MRI datasets in patient cohort
1 and identiﬁed only those with unequivocal ileal disease
on conventional MRI sequences using standard criteria
[19]. After a wash out period of 1 month following the
qualitative grading, the 2 readers reviewed the DWI
images of the selected subset of cohort 1 and all cohort 2
datasets blinded to clinical data, conventional MRE se-
quences, and ADC maps. Quantitative analysis of the
DWI data was performed independently by each of the
readers. Specifically, regions of interest (ROIs) were
placed using OsiriX on the DWI images in the wall of the
most abnormal area of ileum (cohort 1) or terminal ilium
with 5 cm of the ileocecal valve (cohort 2). The ROI was
placed initially on the highest B-value image
(B = 600 mm2/s (1.5T) or B = 800 mm2/s (3T). In or-
der to mitigate against bowel wall movement, the regions
of interest were automatically propagated throughout
the DWI dataset by the software and then manually
readjusted such that they remained anatomically con-
stant.
The conventional monoexponential diffusion model
S = S0.exp(-b.ADC) was fitted to the data to estimate
a single diffusion coefficient, ADC from each ROI. The
mean ADC for the two readers was calculated for each
patient and used for subsequent analysis.
Reference standards-Segmental disease activity.
(a) Histopathology activity score. In each patient from
cohort 2, the terminal ileal biopsies were stained with
haematoxylin–eosin and retrospectively reviewed by
an experienced pathologist >10 years of experience,
who was unaware of clinical information or MRI
findings. The histopathologist applied an endoscopic
biopsy acute inflammatory score (eAIS: Table 3)
based on the typical morphological features of
Crohn’s disease described in guidelines published by
the European Crohn’s and Colitis Organization [20]
first proposed by Steward et al [1]. At least three
samples of terminal ileum biopsy were collected for
each patient, and the highest score for each was used
for that patient, in accordance with the standard
procedure in our institution.
(b) Conventional MRI activity score. For the subset of
patients from Cohort 1 with ileal disease, the MEGS
scores for the ileum and terminal ileum were summed
to give a combined total ileal score (iMEGS).A cut-off
of>10 points was used to define active disease based
on the previous MEGS validation work, in which a
score of <10 indicated a segment with little or no
disease activity (equivalent to a score of 0 or 1 for each
individual parameter comprising the score) [8].
Statistical methods
Statistical analysis was performed using JMP v10 (SAS
Institute Inc., Cary, NC, USA). Shapiro–Wilk W test
was used to evaluate for normal distribution of data.
Table 3. Histopathology grading for acute inflammation score (AIS)
Histological variable Grade
Erosion or ulceration 0 = No, 1 = Yes
Polymorphs in the lamina propria 0 = No, 1 = Yes
Cryptitis 0 = No, 1 = Yes
Crypt abscess formation 0 = No, 1 = Yes
Inflammatory exudates 0 = No, 1 = Yes
Granulomas 0 = No, 1 = Yes
Fig. 1. Example diffusion images demonstrating scoring
schema. A Probably Normal (grade 1). B = 600 image of
small bowel showing pelvic ileal loops with probably normal
(grade 1) DWI signal. B Probably Abnormal (grade 2):
B = 600 image of small bowel showing moderately high signal
ileum (arrow). C Definitely Abnormal (grade 3): B = 600 im-
age of small-bowel very high-signal terminal ileum (arrow).
D. A. Pendse´ et al.: Diffusion-weighted imaging for evaluating inflammatory activity in Crohn’s disease
The primary set of analysis assessed the qualitative
grading of enteric DWI signal to evaluate global
inﬂammatory disease burden.
Speciﬁcally, all cohort 1 patients were grouped into
either grade-0 and grade-1 (normal) or grade-2 and
grade-3 (abnormal) DWI abnormality and calprotectin
level compared between the two groups using the Mann–
Whitney U test. The analysis was repeated using MEGS,
as the second global reference standard.
Thereafter, in those with abnormal (grade 2 and 3)
DWI, calprotectin levels were compared across those
with abnormality in (i) <10 cm of small bowel, (ii)
‡10 cm of small bowel, (iii) both small bowel and colon,
and (iv) colonic only using Kruskal–Wallis test with post
hoc correction.
Finally, the theoretical diagnostic beneﬁt of adding
DWI grading to conventional MEGS in predicting
disease activity based on the calprotectin reference
alone was evaluated. Patients in cohort 1 were divided
into two groups using a previously proposed calpro-
tectin cut-off of ‡120 lg/l for active disease (vs.
<120 lg/l for nonactive disease) [21]. The sensitivity
and specificity of DWI alone (taking grade 2 or 3 to be
active), MEGS alone (taking >10 points to be active),
and combined MEGS plus DWI for active disease were
calculated.
The secondary set of analysis evaluated qualitatively
grading of DWI images and calculated ADC measure-
ments for assessing segmental disease activity.
Bland–Altman analysis was used to test agreement
between all ADC measurements in both study cohorts
made by the 2 readers. The mean of the 2 readers’
measurements was used in subsequent analysis.
Using the histopathological standard of reference
(cohort 2), ADC values were compared between patients
with no histological inﬂammation (eAIS = 0) and those
with histopathological inﬂammation (AIS score ‡1)
using the Mann–Whitney U test. eAIS scores were then
compared across qualitative DWI grades using Kruskal–
Wallis test with post hoc correction. The sensitivity and
specificity of DWI grades 2 and 3 for active disease (AIS
>1) were calculated.
Using the conventional MRI activity score as the
standard of reference (cohort 1 with unequivocal ileal
disease), the correlation between ADC and iMEGS was
tested using Pearson rank correlation. Thereafter, pa-
tients were grouped into either active or nonactive seg-
mental disease based on an iMEGS of >10 points, and
ADC compared between the two groups using the
Mann–Whitney U test.
The accuracy of ADC in predicting the presence of
inﬂammation on biopsy (eAIS >0) was quantiﬁed by
calculating the area under the receiver operating char-
acteristic (ROC) curve.
Results
Patient demographics
There were 71 patients (35 male, age 16–78) in cohort 1.
Two patients were excluded due to the absence of DWI
data leaving 69 patients.
Cohort 2 consisted of 29 patients (19 male, age
16–70). The mean time between colonoscopy and biopsy
and MRI was 2 days (range 0–37 days).
Baseline patient characteristics are shown in Table 1.
Qualitative grading of enteric DWI for evaluating global
disease inﬂammatory activity
Qualitative global DWI grading. 20 of 69 patients (29%)
were evaluated as having grade 1 (probably normal)
DWI on visual assessment, 17 (25%) grade 2 (probably
abnormal), and 32 (46%) grade 3 (deﬁnitely abnormal)
DWI. No patients were assigned grade 0.
Based on the extent of abnormal DWI (grade 2 and
3), 30 patients had <10 cm of small-bowel abnormality,
15 ‡ 10 cm of small-bowel abnormality, 11 small-bowel
and colon abnormality, and 13 colonic abnormality only.
Calprotectin Reference standard. Mean calprotectin
(fC) was 398 lg/g (range 0–1970). The fC was increased
(>120 lg/g) in 44/69 (64%).
Patients with normal (grade 1) DWI had signiﬁcantly
lower mean calprotectin level than those with abnormal
(grades 2 and 3) DWI (160 ± standard deviation (SD)
257 lg/l vs. 492 ± SD 422 lg/l) (p = 0.0004) (Figure 2).
Calprotectin levels were signiﬁcantly lower in those
with abnormal DWI limited to <10 cm of small-bowel
compared to those with abnormal DWI involving both
the small and large bowel [(236 ± SD 302 lg/l vs.
571 ± SD 390 lg/l) (p = 0.009 assuming an adjusted
alpha-level of 0.0125] (Fig. 2)
Global MRI activity score (MEGS) reference stan-
dard. Mean MEGS was 15.8 (range 0–65). MEGS was
increased (> 10) in 35/69 (51%)
When using MEGS as the standard of reference, pa-
tients with normal DWI grades had signiﬁcantly lower
MEGS than those with abnormal DWI grades (3.3 ± SD
5.5 vs. 21 ± SD 18) (p < 0.0001) (Figure 2).
Diagnostic performance of DWI for detecting active dis-
ease. The sensitivity and speciﬁcity of abnormal DWI
(grades 2 and 3) for detecting biochemically active dis-
ease (deﬁned by calprotectin > 120 lg/l) were 83% (95%
CI 69% to 92%) and 52% (95% CI 31% to 73%),
respectively, whereas for MEGS alone they were 88%
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(73% to 97%) and 54% (95% CI 37% to 71%). Combining
DWI with MEGS produced marginal beneﬁt with sen-
sitivity of 91% (95% CI 76% to 98%) and speciﬁcity 56%
(95% CI 38% to 72%).
Comparison of qualitatively graded DWI signal with cal-
culated ADC measurements for evaluating segmental dis-
ease activity
Quantitative DWI evaluation. There was no signiﬁcant
difference in the mean ADC between those measured
with 1.5T (1679 ± SD 496 9 10-6mm2/s) and 3.0T
(1596 ± SD 414 9 10-6mm2/s) scanners (p = 0.6).
Mean ROI size for all ADC measurements was
0.81 ± SD 0.65 cm2 for observer 1 and 0.72 ± SD
0.58 cm2 for observer 2.
A Bland–Altman plot of reader agreement for all
ADC measurements is shown in ﬁgure 3. The 95% limits
of agreement were +52 and +329 9 10-6 mm2/s, with a
mean difference of 226 9 10-6 mm2/s.
Conventional MRI activity score reference standard
33 patients (17 male, age 18–62) in cohort 1 had unequiv-
ocal ileal disease based on conventional MRE criteria.
Overall, 17/33 (52%) hadnonactivedisease (iMEGS < 10)
and 16/33 (48%) had active disease (iMEGS > 10).
There was a moderate negative correlation between
iMEGS and mean ADC across the 2 readers (r = -0.41,
p = 0.017)
Mean ADC in patients with inactive disease based on
conventional MRI was not signiﬁcantly different than
those with active disease (1801 ± 537 9 10-6 mm2/s vs.
1473 ± 278 9 10-6 mm2/s) p = 0.10 (Fig. 4).
Histopathology activity score reference standard. His-
tological eAIS scores from cohort 2 patients ranged from
0 to 4. Seven patients had an eAIS score of 0, and
inﬂammation (AIS > 1) was present in 22/29 (76%).
Qualitative DWI
For qualitative grading of the terminal ileal DWI signal,
6 patients (21%) were assigned grade 1, 9 (31%) grade 2,
and 14 (48%) grade 3.
There was no signiﬁcant difference in eAIS between
qualitative DWI scores (p = 0.42).
The sensitivity and speciﬁcity of abnormal (grades 2
and 3) diffusion score for histological activity
Fig. 2. Boxplots illustrating
qualitative DWI grading
against faecal Calprotectin
and MEGS (median values,
quartiles, and range).
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(eAIS > 1) were 82% (95% CI 60% to 95%) and 29%
(95% CI 4% to 71%).
Quantitative DWI
The mean ADC in those without inﬂammation was not
signiﬁcantly different from patients with inﬂammation
(2077 ± SD 696 9 10-6 mm2/s vs. 1622 ± SD 367
respectively) (p = 0.10) (Fig. 5)
ROC analysis of ADC as predictor of the presence
(AIS > 0) or absence (AIS = 0) of pathological
inﬂammation on biopsy had an area under the curve
(AUC) of 0.71 with sensitivity of 86% and speciﬁcity of
58% at ADC = 1926 9 10-6 mm2/s.
Discussion
This study aimed to evaluate the accuracy of subjective
grading of DWI signal and objective measurement of
ADC in grading of Crohn’s disease activity using a range
of segmental and global standards of reference.
Our results were variable, with some data supporting
the use of qualitative rather than quantitative DWI
grading, but little evidence of utility of either against a
segmental histopathological reference.
Although assessment of disease activity is vital in
management of Crohn’s disease, there is no single ac-
cepted standard of reference with clinical scores, endo-
scopic, pathological, and biochemical markers used in
clinical practice. In the present study, we used 3 reference
standards: (1) faecal calprotectin, a biochemical marker
of global gut inﬂammation; (2) a validated MRI global
and segmental activity score [8]; and (3) histopathologi-
cal analysis of endoscopic terminal ileal biopsy.
We found faecal calprotectin levels were signiﬁcantly
greater (reﬂecting greater disease activity) when enteric
DWI was abnormal. The ﬁndings were similar when
using MEGS as the standard of reference. The presence
of any abnormal DWI signal had 83% sensitivity for
active disease based on faecal calprotectin. However,
speciﬁcity was very low at just 52%. We tested the the-
oretical addition of DWI to conventional MRI activity
grading using MEGS and found a marginal beneﬁt in
terms of detecting active disease based on the calpro-
tectin reference (increasing sensitivity from 88% to 91%).
Our data are broadly similar to that of Kim et al, who
also reported a small improvement in sensitivity for bo-
wel inﬂammation by adding DWI to conventional se-
quences, at the expense of reduced speciﬁcity [22]. These
data suggest DWI cannot replace conventional imaging
sequences and is at best an adjunct to be used in com-
bination. Although recent data suggest DWI may be able
to replace contrast-enhanced imaging in standard pro-
tocols [5], it is clear that conventional MRI sequences are
vital in maintaining specificity.
Fig. 3. Bland–Altman plot illustrating reader Agreement for
ileal ADC measurement.
Fig. 5. Boxplots illustrating ADC (median values, quartiles,
and range) grouped by the histological eAIS score.
Fig. 4. Boxplots illustrating calculated ileal ADC (mean of 2
readers) in patients with nonactive disease (iMEGS < 10)
and active disease (iMEGS > 10). Boxplots showing median
values, quartiles and range. There was no significant differ-
ence in cADC between the groups p = 0.10.
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We did however ﬁnd evidence that the longitudinal
extent of DWI abnormality in the small bowel and colon
was related to calprotectin level, i.e., in general, the more
widespread the DWI abnormality, the greater the cal-
protectin level and inﬂammatory disease burden. A rapid
review of DWI images noting the severity and extent of
abnormal DWI signal may therefore provide a conve-
nient and efﬁcient method of assessing overall activity in
patients with already known disease on conventional
sequences. Such an approach could be useful in assessing
treatment effect by rapidly comparing pre- and post-
DWI imaging, for example.
To our knowledge, this is the ﬁrst work to compare
DWI with calprotectin. One advantage of calprotectin is
that it better reﬂects total inﬂammatory burden than
segmental references such as endoscopy which can assess
at most the colon and terminal ileum. It does have lim-
itations however. It may better reﬂect colonic rather than
small-bowel Crohn’s disease [23], and levels are not
necessarily linearly related to activity. These levels may
also not be increased in the presence of active disease, or
conversely may be falsely increased in the absence of
inflammation [24]. Many workers have therefore com-
pared DWI with conventional MRI activity scores,
which we also explored in the present study. Hordonneau
et al, for example, found the subjective presence of
abnormal DWI had high sensitivity for segmental disease
activity defined by a Maria score >7 [13]. Our data also
suggested a relationship between DWI and an MRI
activity score [8], although not as strong as those re-
ported by Hordonneau et al. An important strength of
the present study is that readers were fully blinded to
conventional MRI sequences when grading DWI signal.
Such an approach better isolates the true diagnostic
worth of DWI and limits the major risk of incorporation
bias when MRI is used as a standard of reference for new
sequences.
Our data regarding the utility of quantitative ADC
measurement was relatively poor. Similar to previous
work [13], we did find a negative correlation between
ADC and a segmental MRI activity score, although the
strength of this association was weak.
Against a histopathological score of activity, neither
qualitative segmental DWI grades nor ADC measure-
ment showed a statistically signiﬁcant relationship to the
level of inﬂammation. This is at odds to previous studies
which have shown reasonable correlations between both
ADC and subjective DWI grading and an endoscopic
standard of reference [16, 22].
Part of the discrepancy could in part be due to the
standard of reference employed. The histopathological
score is a based on mucosal biopsy whereas ADC mea-
surements are taken from the whole bowel wall. The
pathological scoring system has however been employed
with success in other imaging studies [1, 25]. Further-
more, endoscopic standards of reference also suffer from
the same limitation of assessing only the bowel mucosa
and not the full transmural disease extent. Of note, in a
detailed imaging–pathological correlation study using
surgical resection specimens, Tielbeck et al found no
association between ADC and a full wall thickness his-
tological score of inflammation [26] which concurs with
our findings.
Quantitative DWI analysis, with calculation of ADC,
is a complex task. Several post-processing steps are
necessary. First of all, regions of interest must be placed
on the diffusion image sequences. These are then either
transferred to the post-processed ADC maps for ADC
calculation, or (as was performed in this study) the ROI
is propagated through the each DWI sequence and the
ADC values calculated directly.
Themeasurement ofADC in bowel is often difﬁcult due
to the relatively thin bowelwall, given the typical image slice
thickness (normal bowel wall 1–2 mm, typical DWI slice
thickness 5–8 mm). Bowel peristalsis during image acqui-
sition introduces further error. These errors can be limited
by shortening image acquisition time (e.g., fewer signal
averages), but at the expense of a reduction in signal to
noise. It is perhaps not surprising that interobserver
agreement for measurement of ADC was poor between 2
readers in the present study. Indeed, it could be argued that
the apparent reported reduction inADC in active disease is
in part due to overestimating ADC in the thin wall of nor-
mal bowel or that affected by ﬁbrotic disease. Wall thick-
ness per se is a strong predictor of activity [8–10, 27], and
measurement of ADC is easier in thickened bowel.
There are several limitations in this study. We used
both prospectively recruited and retrospectively identiﬁed
cohorts, although this was deliberate given our wish to
apply a variety of reference standards. Patient numbers in
each group were reasonable but not informed by any
power calculation. As noted above, there is no single ac-
cepted reference standard for activity. By using calpro-
tectin, an MRI activity score, and histopathology, we
attempted to capture the strengths of several alternatives
but did not employ others such as endoscopy grading or
surgical specimens. We acquired data on 1.5 T and 3 T
MRI, although we found no difference in ADC measure-
ments between these two platforms. As noted above, a
strength of our methodology is that we blinded readers to
all conventional sequences when evaluating DWI to truly
isolate its diagnostic potential. In clinical practice, this is
not how DWI is employed. Similarly, the study design
utilized consensus reading of DWI data, which may limit
the generalizability of these results. TheMR protocol was
originally designed to allow biexponential quantiﬁcation
of diffusion data and therefore used many B-factors. Al-
though the IVIMmodel has been shown to be of value [12],
this protocol increases scan time significantly and there-
fore is prone to image degradation from bowel movement.
In conclusion, qualitative (visual inspection) assess-
ment of DWI is a reasonably sensitive tool for detection of
D. A. Pendse´ et al.: Diffusion-weighted imaging for evaluating inflammatory activity in Crohn’s disease
bowel inﬂammation in Crohn’s disease based on a cal-
protectin (but not histopathological) standard of reference
but has poor speciﬁcity and cannot fully replace conven-
tional sequences. Its ability to grade the severity of
inﬂammation is however limited. In those with known
disease, rapid review of DWI could give a reasonable
estimate of the overall active disease burden. The addition
of DWI to conventional MR enterography sequences has
a marginal beneﬁt in increasing diagnostic accuracy.
Quantitative ADC measurements are prone to poor
interobserver agreement, have lower discriminatory ability
for active disease, and are therefore not recommended.
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